Skip to main content
Premium Trial:

Request an Annual Quote

Prenetics Authorizes $20M Share Buyback

NEW YORK – Prenetics Global said on Wednesday that its board of directors has authorized the repurchase of up to $20 million of its class A ordinary shares. The company also announced that it has been included as a constituent stock in the MSCI Global Micro Cap Index (Hong Kong).

The diagnostics and genetic testing company, headquartered in Hong Kong, said the repurchase will be executed through open market transactions or in privately negotiated transactions during a 24-month period. The firm said it plans to fund the repurchase program with cash and cash equivalents on hand or future cash flow.

"Our announcement today of our share repurchase program demonstrates our commitment to deliver long-term value to our shareholders," Prenetics CEO and Cofounder Danny Yeung said in a statement.

According to Yeung, the company’s business fundamentals "remain strong with a very healthy balance sheet of $250 million in net current assets."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.